Hennessy Capital Acquisition Corp. II Announces Record and Meeting Dates for Special Meeting of Stockholders to Approve Merger with Daseke, Inc.

HOUSTON, Jan. 30, 2017 (GLOBE NEWSWIRE) — Hennessy Capital Acquisition Corp. II (NASDAQ:HCAC) (NASDAQ:HCACU) (NASDAQ:HCACW) (“HCAC” or the “Company”) today announced that HCAC has set a record date of January 31, 2017 (the “Record Date”) and a meeting date of February 27, 2017 for the special meeting of HCAC stockholders (the “Special Meeting”) to approve...
Read More →

USF Researcher Develops Therapeutic Vaccine to Combat Alzheimer’s Disease and Neurodegenerative Disorders

//
Categories
Chuanhai Cao Chuanhai Cao, PH.D. Assistant Professor, Non USF Health Assoc Professor, Cop Dept of Pharmaceutical Science Assistant Professor, College of Medicine Neurology Associate Professor, Pharmaceutical Sciences, College of Pharmacy Alzamend Neuro, Inc., the USF Technology Transfer Office and the USF Health Byrd Alzheimer’s Institute SALT LAKE CITY, Jan. 30, 2017 (GLOBE NEWSWIRE) — Alzamend...
Read More →

Energy Management System Market to hit $38bn by 2024: Global Market Insights Inc.

Ocean View, Delaware, Jan. 30, 2017 (GLOBE NEWSWIRE) — The industry analysis report “Energy Management System (EMS) Market Size By Component (Metering And Field Equipment, Hardware, Software, Networking Device, Control Systems, Sensors), By Service (IEMS, BEMS, HEMS), Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, France, Italy, Spain, China, Japan, South Korea, India, Indonesia,...
Read More →

Is QUALCOMM, Inc. (QCOM) Stock A Good Buy Following Its Latest Earnings?

Qualcomm, Inc delivered mixed Q1 earnings amidst mounting legal troubles. Is it the right time to buy QCOM stock? Flickr San Diego based Qualcomm, Inc. (NASDAQ:QCOM) reported its Q1 earnings on January 25th, delivering an earnings beat but missing revenue estimates. The largest smartphone chipmaker’s last quarter was overshadowed by its legal disputes. The Street was expecting...
Read More →

Diaxonhit : augmentation de capital d'un montant maximal de 8,9M€ dans le cadre de l'acquisition d'Eurobio

Communiqué Diaxonhit en pdf.pdf COMMUNIQUE DE PRESSE Diaxonhit lance une augmentation de capital avec délai de priorité d’un montant maximal de 8,9 millions d’eurosdestinée à financer une partie de l’acquisition d’Eurobio          Offre au public en France et placement institutionnel du 30 janvier au 3 février 2017 inclus Suppression du droit préférentiel de souscription par voie...
Read More →